Mr. Josh Bartch reports

MYDECINE INNOVATIONS GROUP ANNOUNCES EXPECTED U.K. DUAL LISTING ADMISSION DATE

Mydecine Innovations Group Inc. expects admission of its common shares for trading on the Access Segment of the AQSE Growth Market in the United Kingdom will take place on Oct. 10, 2023. The AQSE Growth Market is a multilateral trading facility operated by Aquis Stock Exchange. A copy of the application announcement can be accessed on-line.

Management commentary:

Josh Bartch, chief executive officer of the company stated: "We have been working diligently to dual list our securities on the AQSE over the last several months and we are excited to have a projected trade date. We have been hard at work over the past year streamlining the company to ensure long-term sustainability, all while advancing our NCE programs forward. We are extremely excited about having further exposure in the U.K. which we feel is a great environment for our mission and vision moving forward. Listing on the AQSE offers a chance at increased investor exposure as well as liquidity. We look forward to increasing communication with the investment community on various advancements in our programs. These are exciting times for the industry as a whole and Mydecine alike."

About Mydecine Innovations Group Inc.

Mydecine Innovations Group is a publicly traded, prerevenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction and posttraumatic stress disorder, along with neurodegenerative disorders.

We seek Safe Harbor.